Navigation Links
Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
Date:3/7/2011

their patients' tumorgrafts and understand the genetic make-up of their patient's tumor enabling them to better select treatment regimens that may be efficacious to the patient.

As we expanded our number of Tumorgraft models, we began to offer leading pharmaceutical and biotechnology companies the benefits of our Tumorgraft Technology Platform for their pharmaceutical development programs.  We provide Translational Oncology Solutions, or TOS, (previously referred to as Preclinical eValuation services) that we believe are predictive of clinical outcomes and that might provide for a faster and less expensive path to drug approval.  These services utilize Tumorgrafts to evaluate tumor sensitivity/resistance to various single, combination standard and novel chemotherapy agents.  TOS also includes biomarker discovery and the identification of novel drug combinations.  We began deriving revenues from our TOS services in fiscal 2009 and completed our first full year of business in fiscal 2010.

Full details of the Company's financial results will be available in the Company's Form 10-Q at www.championsbiotechnology.com.

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties.  Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements.  One should not place undue reliance on these forward-looking statements.  The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors.  See Champions Biotechnology's Form 10-K for the fiscal year ended April 30, 2010 for a discussion of such risks, uncertainties and other factors.  Although the Co
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Biotechnology Reports Additions to its Management Team
2. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
3. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
4. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
5. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
6. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
7. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
8. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
9. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
10. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
11. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) ... changes to Martine Rothblatt , Ph.D,s compensation program. ... United Therapeutics announced the promotion of Roger Jeffs ... David Zaccardelli , Pharm.D. to Executive Vice President ... Dr. Rothblatt,s title will change from Chairman and Chief ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
(Date:12/15/2014)... 15, 2014 METTLER TOLEDO is ... tool, ParticleView V19 with PVM technology , ... particle vision and measurement tool continuously captures high-resolution ... ParticleView V19 then automatically prepares a report pairing ... size and concentration changes. This compelling blend of ...
(Date:12/15/2014)... SAN DIEGO , Dec. 15, 2014 /PRNewswire/ ... a three-dimensional biology company focused on delivering breakthrough ... by the industry and collaborators of its exVive3D ... was made widely available in full commercial release ... in the field, resulting in several awards for ...
Breaking Biology Technology:United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3
... Nov. 10, 2011 ChemoCentryx, Inc. today announced positive ... 44th Annual Meeting of the American Society of Nephrology. ... robust improvements of albuminuria, serum markers of renal function, ... poster presentation titled "CCR2 Inhibition in Diabetic Mice Results ...
... CRANBURY, N.J., Nov. 10, 2011 Palatin Technologies, Inc. (NYSE ... fiscal year 2012 financial results on Tuesday, November 15, 2011 ... Palatin will also conduct a conference call and live audio ... 2011, which will include discussion of the results of operations ...
... a material that absorbs on average more than 99 ... that hits it -- a development that promises to ... of engineers at NASA,s Goddard Space Flight Center in ... Optics and Photonics conference, the largest interdisciplinary technical meeting ...
Cached Biology Technology:ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 2ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology 3Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011 2NASA develops super-black material that absorbs light across multiple wavelength bands 2NASA develops super-black material that absorbs light across multiple wavelength bands 3
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/11/2014)... CHICAGO , Nov. 11, 2014  Forensicon, Inc., ... eDiscovery firm, is pleased to announce the promotion of ... to Director of Digital Forensics. In Schiff,s new role ... out the team of digital forensics examiners and provide ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
... November 18, 2009Quantitative polymerase chain reaction (qPCR) technology ... expansion as a result of advances such as ... optimization-free multiplexing, reports Genetic Engineering & Biotechnology News ... simultaneously quantify specific DNA sequences is increasing its ...
... moa, a giant extinct bird, has revealed a new geological ... in the Proceedings of the National Academy of Sciences ... University of Adelaide has reconstructed a history of marine barriers, ... of years, using the first complete genetic history of the ...
... , , KIEV, Ukraine, Nov. 17 ... including designer fashions, precious gems, antiques and fine art, has ... around the world. The International Chamber of Commerce estimates ... However, an exciting new technology can give brands and ...
Cached Biology News:Extinct moa rewrites New Zealand's history 2Innovative Document Security Technology Proves Powerful in Avoiding Counterfeit Products 2Innovative Document Security Technology Proves Powerful in Avoiding Counterfeit Products 3
... binding specificity and signaling of the members ... be modified by alternative splicing--which has important ... you can perform a classical expression profiling ... different alternatively spliced forms of the gene ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... Visualizer Extraction Kit is manufactured for DNA ... damage byexposure to UV light. The Purification ... often used for DNA-cloning work. The conventional ... and exposure of UV light damages DNA ...
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
Biology Products: